A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-site, Proof of Concept Trial to Evaluate the Efficacy and Safety of LEO 138559 in Adult Subjects With Moderate to Severe Atopic Dermatitis (AD).
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 58
- 试验地点
- 2
- 主要终点
- Change in EASI Score From Baseline to Week 16
研究概览
简要总结
This is a clinical study in adult participants with moderate to severe atopic dermatitis (AD).
The purpose of the study is to test a new medicine (LEO 138559) given by injection to see if it works to treat AD and what the side effects are when compared with a placebo injection with no medical ingredient.
The study will last up to 36 weeks for each participant. The study will include a treatment period of 16 weeks, during which the participants will receive the injections, followed by a period of 16 weeks without treatment with the main purpose of continuing safety evaluations. The participants will regularly visit the clinic for tests and the study doctor will evaluate their AD. The participants will also be asked to answer questions about their AD symptoms and quality of life.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-64 years old (both included) at screening.
- •Diagnosis of atopic dermatitis (AD) (as defined by the American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year prior to screening.
- •Subjects who have a recent history (within 6 months before screening) of inadequate response to treatment with topical medication, or for whom topical treatments are otherwise medically inadvisable.
- •Eczema Area and Severity Index (EASI) score ≥12 at screening and ≥16 at baseline.
- •Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score ≥3 at screening and baseline.
- •Body surface area (BSA) of AD involvement ≥10% at screening and baseline.
- •Worst Daily Pruritus Numeric Rating Scale (NRS, weekly average) of ≥3 points at baseline.
排除标准
- •Treatment with systemic immunosuppressive/immunomodulating medication, immunoglobulin/blood products, or phototherapy within 4 weeks or 5 half-lives prior to randomization, whichever is longer.
- •Treatment with biologics within 5 half-lives (if known) or 16 weeks prior to randomization, whichever is longer.
- •Treatment with topical corticosteroid(s) (TCS), topical calcineurin inhibitor(s) (TCI), topical phosphodiesterase-4 (PDE-4) inhibitor, or other topical prescription treatments within 1 week prior to randomization.
- •Treatment with a live (attenuated) vaccine within 12 weeks prior to randomization.
- •Clinically significant active chronic or acute infection requiring systemic treatment within 4 weeks prior to randomization that may compromise the safety of the subject.
- •Skin infection within 1 week prior to the baseline visit.
- •Presence of hepatitis B or C infection at screening.
- •History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.
- •Participant has a positive or indeterminate test for tuberculosis at screening.
- •Participant is pregnant or lactating.
研究组 & 干预措施
LEO 138559
Participants will receive injections of LEO 138559 from Week 0 (baseline) to Week 16 (end of treatment).
干预措施: LEO 138559 (Drug)
Placebo
Participants will receive injections of placebo from Week 0 (baseline) to Week 16 (end of treatment).
干预措施: LEO 138559 placebo (Drug)
结局指标
主要结局
Change in EASI Score From Baseline to Week 16
时间窗: Week 0 to Week 16
The Eczema Area and Severity Index (EASI) is a validated measure used in clinical trials to evaluate the extent and severity of atopic dermatitis. EASI is a composite score ranging from 0 to 72 with higher scores indicating a more extensive and/or severe condition.
次要结局
- Number of Treatment-emergent Adverse Events From Baseline to Week 16 Per Subject(Week 0 to Week 16)